Targeted biopsy based on ADC map in the detection and localization of prostate cancer: A feasibility study

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 5, 2013, Pages 1168-1177

  Watanabe, Yuji ^a   Nagayama, Masako ^a   Araki, Tohru ^b   Terai, Akito ^a   Okumura, Akira ^a   Amoh, Yoshiki ^a   Ishimori, Takayoshi ^a   Nakashita, Satoru ^a   Dodo, Yoshihiro ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b Araki Urology Clinic   (Japan)

Author keywords

apparent diffusion coefficient; diffusion weighted imaging; magnetic resonance imaging; prostate cancer; targeted biopsy; transition zone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CHRONIC PROSTATITIS; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; ALGORITHMS; BIOPSY, LARGE-CORE NEEDLE; FEASIBILITY STUDIES; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE-GUIDED BIOPSY; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; MIDDLE AGED; PATTERN RECOGNITION, AUTOMATED; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84876498100     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23908     Document Type: Article

References (38)

1. Claus FG, Hricak H, Hattery RR,. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 2004; 24 (Suppl 1): S167-180.
2. Mullerad M, Hricak H, Kuroiwa K, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005; 174: 2158-2163.
3. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164: 400-404.
4. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL,. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24: 108-113.
5. Tamada T, Sone T, Toshimitsu S, et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging 2008; 27: 552-556.
6. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S,. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-152.
7. Nagayama M, Watanabe Y, Terai A, et al. Determination of the cutoff level of apparent diffusion coefficient values for detection of prostate cancer. Jpn J Radiol 2011; 29: 488-494.
8. Watanabe Y, Terai A, Araki T, et al. Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC Map: A prospective large-scale cohort study. J Magn Reson Imaging 2012; 35: 1414-1421.
9. Delongchamps NB, Haas GP,. Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol 2009; 6: 645-652.
10. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J,. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 1605-1612.
11. Presti JC,. Prostate biopsy: current status and limitations. Rev Urol 2007; 9: 93-98.
12. Ravery V, Szabo J, Toublanc M, et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996; 77: 724-728.
13. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP,. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (3 Suppl): 933-938.
14. Singh AK, Kruecker J, Xu S, et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 2008; 101: 841-845.
15. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-792.
16. Ishida J, Sugimura K, Okizuka H, et al. Benign prostatic hyperplasia: value of MR imaging for determining histologic type. Radiology 1994; 190: 329-331.
17. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008; 27: 132-139.
18. Ellis WJ, Chetner MP, Preston SD, Brawer MK,. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994; 152 (5 Pt 1): 1520-525.
19. Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C,. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 2006; 175: 485-488.
20. Bott SR, Young MP, Kellett MJ, Parkinson MC,. Anterior prostate cancer: is it more difficult to diagnose ? BJU Int 2002; 89: 886-889.
21. Takashima R, Egawa S, Kuwao S, Baba S,. Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology 2002; 59: 692-697.
22. Wright JL, Ellis WJ,. Improved prostate cancer detection with anterior apical prostate biopsies. Urol Oncol 2006; 24: 492-495.
23. Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007; 99: 1484-1489.
24. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005; 21: 258-262.
25. McNeal JE, Redwine EA, Freiha FS, Stamey TA,. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906.
26. Noguchi M, Stamey TA, Neal JE, Yemoto CE,. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000; 163: 1751-1755.
27. Reissigl A, Pointner J, Strasser H, Ennemoser O, Klocker H, Bartsch G,. Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate 1997; 30: 130-135.
28. Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K, Rannikko S,. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol 2001; 42: 348-354.
29. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT,. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243: 28-53.
30. Ren J, Huan Y, Li F, et al. Combined T2-weighted and diffusion-weighted MRI for diagnosis of urinary bladder invasion in patients with prostate carcinoma. J Magn Reson Imaging 2009; 30: 351-356.
31. Naik KS, Carey BM,. The transrectal ultrasound and MRI appearances of granulomatous prostatitis and its differentiation from carcinoma. Clin Radiol 1999; 54: 173-175.
32. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA,. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 30: 327-334.
33. Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005; 22: 639-646.
34. Shukla-Dave A, Hricak H, Eberhardt SC, et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology 2004; 231: 717-724.
35. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249: 900-908.
36. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
37. Nagarajan R, Margolis D, Raman S, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012; 2012: 374805.
38. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV,. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175 (3 Pt 1): 907-912.